Wyeth

Aventis Pharma Deutschland, Gmbh

American Home Products Corporation

Daniel Michael Green

Jay Edward Wrobel

William R Ewing

Jeffrey Claude Pelletier

Yong Mi Choi-Sledeski

Jeffrey N Barton

Charles William Mann

Michael R Becker

Yong Gong

Diane Barbara Hauze

Wenling Kao

Heinz W Pauls

Julian Roy Levell

Kenneth L Kees

Henry W Pauls

Matthew Douglas Vera

James Winfield Jetter

John Francis Rogers, Jr

Joseph Theodore Lundquist, Iv

John F Rogers

John Francis Mehlmann

Lloyd Michael Garrick

Compounds of Formula I, useful as Gonadotropin Releasing Hormone ('GnRH') (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists, are disclosed. 

Gonadotropin releasing hormone receptor antagonists

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds

Aryl sulfonic acids and derivatives as FSH antagonists

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

Growing community of inventors

Ambler, PA, United States of America

Daniel Michael Green